All In Biotech

Drug Trial Radar · NCT07587385

A Study of HS-10506 in Chinese Patients With Insomnia Disorder

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HS-10506 in Chinese Adult Patients With Insomnia Disorder

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 732 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

732

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Jun 28, 2028

Study completion Aug 12, 2028

Sponsor

Sponsor type
Industry
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this phase 3 study is to evaluate the safety and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) and wakefulness after sleep onset (WASO) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.

Conditions

  • Insomnia Disorder

Interventions

  • HS-10506Drug

    HS-10506 tablet

  • PlaceboDrug

    Placebo tablet matched to HS-10506

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline of mean latency to persistent sleep (LPS) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506Time frame: Baseline, Night 27 and Night 28,Night 83 and Night 84
  2. Change from baseline of mean wakefulness after sleep onset (WASO) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506Time frame: Baseline, Night 27 and Night 28, Night 83 and Night 84

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.